Announcements
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
- Organovo to Participate in the H.C. Wainwright Global Investment Conference
- Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
More ▼
Key statistics
As of last trade, Organovo Holdings Inc (0R02:LSE) traded at 1.27, 32.29% above the 52 week low of 0.96 set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.27 |
Average volume | 40.92k |
---|---|
Shares outstanding | 10.04m |
Free float | 9.85m |
P/E (TTM) | -- |
Market cap | 11.55m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 20 minutes, as of Apr 18 2024 18:43 BST.
More ▼